Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
AstraZeneca
Harvard Business School
Covington
Deloitte
Federal Trade Commission
Boehringer Ingelheim
Cerilliant
QuintilesIMS

Generated: May 27, 2018

DrugPatentWatch Database Preview

NEODECADRON Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Neodecadron patents expire, and when can generic versions of Neodecadron launch?

Neodecadron is a drug marketed by Merck and is included in two NDAs.

The generic ingredient in NEODECADRON is dexamethasone sodium phosphate; neomycin sulfate. There are thirty-nine drug master file entries for this compound. Additional details are available on the dexamethasone sodium phosphate; neomycin sulfate profile page.
Summary for NEODECADRON
Drug patent expirations by year for NEODECADRON

US Patents and Regulatory Information for NEODECADRON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck NEODECADRON dexamethasone sodium phosphate; neomycin sulfate OINTMENT;OPHTHALMIC 050324-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck NEODECADRON dexamethasone sodium phosphate; neomycin sulfate SOLUTION/DROPS;OPHTHALMIC 050322-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cerilliant
Moodys
QuintilesIMS
AstraZeneca
Merck
Cipla
Federal Trade Commission
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.